Genetically Engineered and Implantable Mouse Brain Tumor Models: Characterization by Immunohistochemistry and Flow Cytometry
- PMID: 39777911
- PMCID: PMC11731892
- DOI: 10.1002/cpz1.70080
Genetically Engineered and Implantable Mouse Brain Tumor Models: Characterization by Immunohistochemistry and Flow Cytometry
Abstract
Gliomas are aggressive tumors with a poor prognosis. The protocols presented here outline the methods used to study tumor progression, the tumor microenvironment (TME), and the effects of experimental treatments. The Sleeping Beauty (SB) transposase system induces tumors de novo to generate mouse models that recapitulate human gliomas. Plasmids are constructed with oncogenic drivers and other genetic alterations of interest. which are recognized by their unique position in between inverted/direct repeat (IR/DR) sequences. Luciferase enzyme is used to monitor the uptake of the plasmid, tumor growth, and response to experimental therapies. The genes of interest are tracked using fluorescent markers. Tumors will arise in immunocompetent hosts, which provides a relevant preclinical platform for analysis of tumor initiation, progression, survival, immune microenvironment, and histopathological features. Once the tumor grows within the desired brain location, it can be harvested to generate cell cultures of neurospheres for future experimentation. The benefit of implantable models generated from SB tumors is that they provide specific anatomical and genetic context, in which specific genetic characteristics can be tracked, as they are co-expressed with fluorescent markers. Post glioma cell implantation, additional analysis of the TME and tumor growth can be performed through immunohistochemistry (IHC) and flow cytometry. © 2025 Wiley Periodicals LLC. Basic Protocol 1: Creation of mouse glioma models by Sleeping-Beauty-mediated transposition Basic Protocol 2: Generation of orthotopic implantable brain tumors and neurospheres Basic Protocol 3: Hematoxylin and eosin staining of glioma tissue samples Basic Protocol 4: Immunohistochemistry of glioma tissue samples Basic Protocol 5: Flow cytometry for immune cell analysis of the tumor microenvironment.
Keywords: Gliomas; flow cytometry; genetically engineered mouse models; immune microenvironment; immunohistochemistry; preclinical model.
© 2025 Wiley Periodicals LLC.
Conflict of interest statement
Conflict of Interest Statement
The authors declare no conflict of interest.
Similar articles
-
Isolation and characterization of immune cells from the tumor microenvironment of genetically engineered pediatric high-grade glioma models using the sleeping beauty transposon system.Methods Enzymol. 2020;632:369-388. doi: 10.1016/bs.mie.2019.05.023. Epub 2019 Jun 3. Methods Enzymol. 2020. PMID: 32000905 Free PMC article.
-
Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma.Clin Cancer Res. 2020 Aug 1;26(15):4080-4092. doi: 10.1158/1078-0432.CCR-19-3714. Epub 2020 Apr 24. Clin Cancer Res. 2020. PMID: 32332014 Free PMC article.
-
Multiparametric Analyses of Hepatocellular Carcinoma Somatic Mouse Models and Their Associated Tumor Microenvironment.Curr Protoc. 2021 Jun;1(6):e147. doi: 10.1002/cpz1.147. Curr Protoc. 2021. PMID: 34101385
-
Rodent Models to Analyze the Glioma Microenvironment.ASN Neuro. 2021 Jan-Dec;13:17590914211005074. doi: 10.1177/17590914211005074. ASN Neuro. 2021. PMID: 33874781 Free PMC article. Review.
-
Genetically engineered mouse models of brain cancer and the promise of preclinical testing.Brain Pathol. 2009 Jan;19(1):132-43. doi: 10.1111/j.1750-3639.2008.00234.x. Brain Pathol. 2009. PMID: 19076778 Free PMC article. Review.
References
-
- Núñez FJ, Mendez FM, Kadiyala P, Alghamri MS, Savelieff MG, Garcia-Fabiani MB, Haase S, Koschmann C, Calinescu A-A, Kamran N, Saxena M, Patel R, Carney S, Guo MZ, Edwards M, Ljungman M, Qin T, Sartor MA, Tagett R, … Castro MG (2019). Idh1-R132h acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Science Translational Medicine, 11(479). 10.1126/scitranslmed.aaq1427 - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
- R21 NS123879/NS/NINDS NIH HHS/United States
- R01 NS105556/NS/NINDS NIH HHS/United States
- R01 NS082311/NS/NINDS NIH HHS/United States
- R01 NS124167/NS/NINDS NIH HHS/United States
- R01 NS127378/NS/NINDS NIH HHS/United States
- R01 EB022563/EB/NIBIB NIH HHS/United States
- R01 NS076991/NS/NINDS NIH HHS/United States
- R37 NS094804/NS/NINDS NIH HHS/United States
- R01 NS096756/NS/NINDS NIH HHS/United States
- R01 NS122234/NS/NINDS NIH HHS/United States
- R01 NS122165/NS/NINDS NIH HHS/United States
- R01 NS122536/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical